G1 Therapeutics Inc (NASDAQ:GTHX) Receives $65.17 Consensus PT from Analysts

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have earned an average rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $65.17.

GTHX has been the subject of several analyst reports. Wedbush dropped their target price on G1 Therapeutics from $67.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. BTIG Research upped their target price on G1 Therapeutics from $51.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. BidaskClub upgraded G1 Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $74.00 target price on shares of G1 Therapeutics in a research note on Thursday, December 12th.

G1 Therapeutics stock traded up $0.91 during trading on Monday, hitting $12.08. The company’s stock had a trading volume of 209,266 shares, compared to its average volume of 304,795. The stock has a market capitalization of $424.98 million, a price-to-earnings ratio of -3.71 and a beta of 2.11. The stock’s fifty day moving average is $16.27 and its 200 day moving average is $23.18. G1 Therapeutics has a 1-year low of $8.80 and a 1-year high of $41.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.71 and a current ratio of 13.71.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Wednesday, February 26th. The company reported ($0.94) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.02. On average, research analysts anticipate that G1 Therapeutics will post -4 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can acquired a new stake in G1 Therapeutics during the fourth quarter worth about $60,000. Bank of Montreal Can increased its stake in G1 Therapeutics by 43.7% during the fourth quarter. Bank of Montreal Can now owns 4,264 shares of the company’s stock worth $113,000 after acquiring an additional 1,296 shares during the last quarter. Victory Capital Management Inc. increased its stake in G1 Therapeutics by 12.9% during the fourth quarter. Victory Capital Management Inc. now owns 4,646 shares of the company’s stock worth $123,000 after acquiring an additional 531 shares during the last quarter. Quantbot Technologies LP increased its stake in G1 Therapeutics by 186.3% during the fourth quarter. Quantbot Technologies LP now owns 5,950 shares of the company’s stock worth $157,000 after acquiring an additional 3,872 shares during the last quarter. Finally, Hodges Capital Management Inc. acquired a new stake in G1 Therapeutics during the fourth quarter worth about $202,000. Institutional investors own 80.20% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

See Also: What are benefits of a growth and income fund?

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.